| EBV-Related Malignant Neoplasm studied in …STUDIED_INderived10 of 120show all (up to 200) |
|---|
| → studied in | NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 120 trials mapped (21 active) | — | — | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03984448Phase 2/Phase 3 · active not recruiting Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 120 trials mapped (21 active) | — | — | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04799275Phase 2/Phase 3 · active not recruiting Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 120 trials mapped (21 active) | — | — | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06741072Phase 1 · recruiting BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants · condition mapped ONTOLOGY_EXACT · 120 trials mapped (21 active) | — | — | EBV-Related Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01815749Phase 1 · active not recruiting Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 120 trials mapped (21 active) | — | — | Adult Grade III Lymphomatoid Granulomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04664179Phase 1 · recruiting EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma · condition mapped ONTOLOGY_EXACT · 120 trials mapped (21 active) | — | — | EBV-Related Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04925544Phase 2 · active not recruiting Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies · condition mapped ALIAS · 120 trials mapped (21 active) | — | — | EBV-Related Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03038672Phase 2 · active not recruiting Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 120 trials mapped (21 active) | — | — | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07097363Phase 2 · recruiting Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 120 trials mapped (21 active) | — | — | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05507541Phase 2 · active not recruiting TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 120 trials mapped (21 active) | — | — | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |